Through integrated proteomic, phosphoproteomic, and transcriptomic analyses, Yuen Lam Dora Ng et al identified CDK6 upregulation as a druggable target in lenalidomide-resistant MM.[34] Daratumumab, a CD38-targeted monoclonal antibody, primarily exerts antitumor effects through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Here, CDK6 is linked to Miyoshi myopathy.